Search results for "Psoriatic"
showing 10 items of 73 documents
170 Psoriatic arthritis: Predisposing, constitutive and provoking factors
2016
Relationship between clinical variables and Patient-Reported Outcomes in patients with psoriatic disease
2021
Background Psoriatic Arthritis (PsA) is a chronic inflammatory form of Arthritis associated with enthesitis, dactylitis, nail dystrophy, uveitis, and osteitis. PsA is strongly associated with comorbidities such as obesity, metabolic syndrome, and cardiovascular disease. As usual PsA patients are assessed either by rheumatologist or dermatologist but a multiprofessional assessment for those subjects is important to improve their disease control and their quality-of-life. The multidimensional assessment is a new model of care for PsA patients in which a multiprofessional team (rheumatologist, dermatologist, internal medicine physician, nutritionist and a phycologist) with a nurse as case mana…
Reply
2017
IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation
2020
To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome of psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients.
Achilles tendon ultrasonography may detect early features of psoriatic arthropathy in those with cutaneous psoriasis
2014
Psoriatic arthritis and COVID ‐19 pandemic: Consequences in medical treatment?
2020
The COVID‐19 pandemic has a strong negative impact on human society world‐wide. Patients with immune‐mediated disease may be prone to an increased risk of infection and/ or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID‐19 the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID‐19? Does systemic medical treatment pose an increased risk of infection with SARS‐CoV‐2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis ‐ a factor with strong negativ…
Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriati…
2022
Abstract Background Biologics have demonstrated efficacy in PsA in randomized clinical trials. More evidence is needed on their effectiveness under real clinical practice conditions. The aim of the present work is to provide real-world evidence of the effectiveness of biologics for PsA in the daily clinical practice. Methods CHRONOS was a multicenter, non-interventional, cohort study conducted in 20 Italian hospital rheumatology clinics. Results 399 patients were eligible (56.9% females, mean (SD) age: 52.4 (11.6) years). The mean (SD) duration of PsA and psoriasis was 7.2 (6.9) and 15.3 (12.2) years, respectively. The mean (SD) duration of the biologic treatment under analysis was 18.6 (6.…
THE RELATIONSHIP BETWEEN VISCERAL ADIPOSITY INDEX AND DISABILITY FUNCTION IN A COHORT OF PSORIATIC ARTHRITIS PATIENTS
2013
The Respiratory Burst and Psoriasis
1988
Psoriasis is a disease affecting about 1–2% of the population worldwide, similar to diabetes mellitus.1 It occurs somewhat more frequently in the white population than among Asians and Eskimos.1 The disease has two peaks of onset, an early one occurring around the age of 20 and a later one around 60.2 In early-onset psoriasis, 85% of patients exhibit the HLA Cw6 antigen; in the late-onset group, no such pattern of inheritance can be found.2